Hudson Bay Capital Management
ATNM icon

Hudson Bay Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Hudson Bay Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-93,204
Closed -$730K – 776
2024
Q1 		$730K Buy
+93,204
New +$599K ﹤0.01% 567
2019
Q2 		– Sell
-1,410
Closed -$20K – 427
2019
Q1 		$20K Buy
+1,410
New +$22.5K ﹤0.01% 666

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Hudson Bay Capital Management's ATNM Position: Q2 2024 in Review

Hudson Bay Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q2 2024, closing a stake of 93,204 shares — an estimated $730K sold.

Hudson Bay Capital Management first reported a position in ATNM in Q1 2019 and held it in 2 quarters. The position peaked at $730K in Q1 2024. 74 funds tracked by Wall St. Rank hold ATNM as of Q2 2024.

  • Hudson Bay Capital Management reported no remaining Actinium Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 93,204 Actinium Pharmaceuticals shares in Q2 2024, an estimated $730K.
  • Hudson Bay Capital Management first reported a position in Actinium Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Hudson Bay Capital Management's Actinium Pharmaceuticals position peaked at $730K in Q1 2024.
  • 74 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2024.

Based on Hudson Bay Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.